138 related articles for article (PubMed ID: 10942094)
1. Sequence analysis of the HIV-1 protease coding region of 18 HIV-1-infected patients prior to HAART and possible implications on HAART.
Gehringer H; Bogner JR; Goebel FD; Nitschko H; von der Helm K
J Clin Virol; 2000 Aug; 17(2):137-41. PubMed ID: 10942094
[TBL] [Abstract][Full Text] [Related]
2. Variations in HIV-1 pol gene associated with reduced sensitivity to antiretroviral drugs in treatment-naive patients.
Birk M; Sönnerborg A
AIDS; 1998 Dec; 12(18):2369-75. PubMed ID: 9875574
[TBL] [Abstract][Full Text] [Related]
3. [Polymorphism of protease genes in patients infected with HIV-1 and response to therapy including a protease inhibitor].
Mouroux M; Bossi P; Yvon-Groussin A; Delaugerre C; Valantin MA; Tubiana R; Coutellier A; Bonmarchand M; Bricaire F; Katlama C; Agut H; Huraux JM; Calvez V
Pathol Biol (Paris); 1999 May; 47(5):549-52. PubMed ID: 10418038
[TBL] [Abstract][Full Text] [Related]
4. Lack of evidence for protease evolution in HIV-1-infected patients after 2 years of successful highly active antiretroviral therapy.
Parera M; Ibañez A; Clotet B; Martinez MA
J Infect Dis; 2004 Apr; 189(8):1444-51. PubMed ID: 15073682
[TBL] [Abstract][Full Text] [Related]
5. The influence of protease inhibitor resistance profiles on selection of HIV therapy in treatment-naive patients.
Turner D; Schapiro JM; Brenner BG; Wainberg MA
Antivir Ther; 2004 Jun; 9(3):301-14. PubMed ID: 15259893
[TBL] [Abstract][Full Text] [Related]
6. Prevalence of drug resistance-related polymorphisms in treatment-naive individuals infected with nonsubtype B HIV type 1 in Cameroon.
Youngpairoj AS; Alemnji GA; Eno LT; Lyonga EJ; Eloundou MA; Shanmugam V; Mpoudi EN; Folks TM; Kalish ML; Pieniazek D; Fonjungo PN
AIDS Res Hum Retroviruses; 2012 Jul; 28(7):675-84. PubMed ID: 21923557
[TBL] [Abstract][Full Text] [Related]
7. Protease sequences from HIV-1 group M subtypes A-H reveal distinct amino acid mutation patterns associated with protease resistance in protease inhibitor-naive individuals worldwide. HIV Variant Working Group.
Pieniazek D; Rayfield M; Hu DJ; Nkengasong J; Wiktor SZ; Downing R; Biryahwaho B; Mastro T; Tanuri A; Soriano V; Lal R; Dondero T
AIDS; 2000 Jul; 14(11):1489-95. PubMed ID: 10983635
[TBL] [Abstract][Full Text] [Related]
8. Analysis of the protease sequences of HIV-1 infected individuals after Indinavir monotherapy.
Sa-Filho DJ; Costa LJ; de Oliveira CF; Guimarães AP; Accetturi CA; Tanuri A; Diaz RS
J Clin Virol; 2003 Oct; 28(2):186-202. PubMed ID: 12957189
[TBL] [Abstract][Full Text] [Related]
9. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
Van Vaerenbergh K
Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
[TBL] [Abstract][Full Text] [Related]
10. Evolution of the HIV-1 protease region in heavily pretreated HIV-1 infected patients receiving Atazanavir.
Vergani B; Cicero ML; Vigano' O; Sirianni F; Ferramosca S; Vitiello P; Di Vincenzo P; Pia De Pasquale M; Galli M; Rusconi S
J Clin Virol; 2008 Feb; 41(2):154-9. PubMed ID: 18024202
[TBL] [Abstract][Full Text] [Related]
11. Long-term virological outcome and resistance mutations at virological rebound in HIV-infected adults on protease inhibitor-sparing highly active antiretroviral therapy.
de la Rosa R; Ruíz-Mateos E; Rubio A; Abad MA; Vallejo A; Rivero L; Genebat M; Sánchez-Quijano A; Lissen E; Leal M
J Antimicrob Chemother; 2004 Jan; 53(1):95-101. PubMed ID: 14657091
[TBL] [Abstract][Full Text] [Related]
12. Emergence and genetic evolution of HIV-1 variants with mutations conferring resistance to multiple reverse transcriptase and protease inhibitors.
Cabana M; Clotet B; Martínez MA
J Med Virol; 1999 Dec; 59(4):480-90. PubMed ID: 10534730
[TBL] [Abstract][Full Text] [Related]
13. Genotypic resistance profiles in antiretroviral-naive HIV-1 infections before and after initiation of first-line HAART: impact of polymorphism on resistance to therapy.
Sukasem C; Churdboonchart V; Sukeepaisarncharoen W; Piroj W; Inwisai T; Tiensuwan M; Chantratita W
Int J Antimicrob Agents; 2008 Mar; 31(3):277-81. PubMed ID: 18182278
[TBL] [Abstract][Full Text] [Related]
14. Long-term analysis of the resistance development in HIV-1 positive patients treated with protease and reverse transcriptase inhibitors: correlation of the genotype and disease progression.
Václavíková J; Weber J; Machala L; Reinis M; Linka M; Brůcková M; Vandasová J; Stanková M; Konvalinka J
Acta Virol; 2005; 49(1):29-36. PubMed ID: 15929396
[TBL] [Abstract][Full Text] [Related]
15. Differential evolution of Human Immunodeficiency Virus type 1 Protease and Reverse Transcriptase genes between HAART-failing and naïve-treated individuals.
Varella RB; Schrago CG; Zalis MG
Curr HIV Res; 2009 Nov; 7(6):601-5. PubMed ID: 19929796
[TBL] [Abstract][Full Text] [Related]
16. Resilience to resistance of HIV-1 protease inhibitors: profile of darunavir.
Lefebvre E; Schiffer CA
AIDS Rev; 2008; 10(3):131-42. PubMed ID: 18820715
[TBL] [Abstract][Full Text] [Related]
17. Analysis of HIV drug-resistant quasispecies in plasma, peripheral blood mononuclear cells and viral isolates from treatment-naive and HAART patients.
Paolucci S; Baldanti F; Campanini G; Zavattoni M; Cattaneo E; Dossena L; Gerna G
J Med Virol; 2001 Oct; 65(2):207-17. PubMed ID: 11536225
[TBL] [Abstract][Full Text] [Related]
18. HIV-1 drug resistance profiles in children and adults with viral load of <50 copies/ml receiving combination therapy.
Hermankova M; Ray SC; Ruff C; Powell-Davis M; Ingersoll R; D'Aquila RT; Quinn TC; Siliciano JD; Siliciano RF; Persaud D
JAMA; 2001 Jul; 286(2):196-207. PubMed ID: 11448283
[TBL] [Abstract][Full Text] [Related]
19. Mutational patterns and correlated amino acid substitutions in the HIV-1 protease after virological failure to nelfinavir- and lopinavir/ritonavir-based treatments.
Garriga C; Pérez-Elías MJ; Delgado R; Ruiz L; Nájera R; Pumarola T; Alonso-Socas Mdel M; García-Bujalance S; Menéndez-Arias L;
J Med Virol; 2007 Nov; 79(11):1617-28. PubMed ID: 17854027
[TBL] [Abstract][Full Text] [Related]
20. Long-term suppression of plasma viremia with highly active antiretroviral therapy despite virus evolution and very limited selection of drug-resistant genotypes.
Pariente N; Pernas M; de la Rosa R; Gómez-Mariano G; Fernández G; Rubio A; López M; Benito JM; López-Galíndez C; Leal M; Domingo E; Martinez MA; Mas A
J Med Virol; 2004 Jul; 73(3):350-61. PubMed ID: 15170628
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
